DUVNF yields 1548.59% · JNJ yields 2.13%● Live data
📍 DUVNF pulled ahead of the other in Year 1
Combined, DUVNF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DUVNF + JNJ for your $10,000?
Peruvian Metals Corp. engages in the acquisition, exploration for, and development of precious and base metals in Peru. The company holds 100% interests in the Panteria Porphyry Gold - Copper Project that consists of 4 mineral concessions covering an area of 2,000 hectares in south-central Peru; and the Cerro La Cumbre project consists of 2 mineral concessions covering an area of 727 hectares. It also has interests in the Huachocolpa properties that consist of 78 contiguous and non-contiguous mining concessions covering an area of 2,548 hectares located in the Department of Huancavelica; and the Palta Dorada property, which covers an area of 1,200 hectares located in the Ancash Mining Department in northern Peru; the Indio Inka property, which covers an area of 470 hectares located in asphalted road from the Aguila Norte processing plant; and the Minas Yanayco, which covers an area of 500 hectares located in Ancash Department near the small town of Pueblo Libre, as well as the Minas Visca project in northern Peru that covers an area of approximately 94 hectares. The company was formerly known as Duran Ventures Inc. and changed its name to Peruvian Metals Corp. in September 2018. Peruvian Metals Corp. was incorporated in 1997 and is based in Edmonton, Canada.
Full DUVNF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.